SOPHiA GENETICS technology aids NOMAD Genetics
in the advancement of its cancer research capabilities
BOSTON and LAUSANNE, Switzerland, June 15,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:
SOPH), a cloud-native software company in the healthcare space and
a leader in data-driven medicine, today announced a strategic
alliance with NOMAD Genetics. Headquartered in Mexico City and Chile, NOMAD is an innovative laboratory
renowned for its specialization in genomics and clinical research.
Through the seamless deployment of SOPHiA GENETICS' trailblazing
SOPHiA DDM™ Platform, NOMAD Genetics is augmenting its research
capabilities while elevating its operational efficiency.
The SOPHiA DDM™ Platform, known for its sophisticated analytical
capacity, will equip NOMAD Genetics with the power to decipher
intricate genetic data, thereby enabling more proficient and
extensive genomic and clinical studies across the Latin American
region. This collaboration marks an important leap forward in
expanding the horizons of precision medicine, reinforcing SOPHiA
GENETICS' steadfast commitment to democratizing data-driven
medicine.
"At NOMAD Genetics, we work to bring precision medicine to each
patient through our state-of-the-art technology and specific
genomic panels for each type of cancer," said Guillermo Cordero, NOMAD Genetics CEO. "Here at
NOMAD Genetics, we strive to revolutionize patient care by
delivering personalized precision medicine. Utilizing our
cutting-edge technology and bespoke genomic panels tailored to each
unique cancer type, we endeavor to advance the boundaries of
medicinal care."
HRD is caused by a cell's impaired ability to repair DNA
double-stranded breaks through the homologous recombination repair
(HRR) pathway and is linked with the development of certain
cancers, including advanced ovarian cancer, as well as breast,
prostate, and pancreatic cancers. For those diagnosed with
these cancer types, HRD can be used as a potential predictive
biomarker for therapy response1.
Testing for HRD can produce a vast set of complex data that is
both time-intensive and costly to analyze. With the SOPHiA GENETICS
Platform, laboratories like NOMAD Genetics can quickly obtain
interpreted results, creating increased efficiencies for clinical
researchers. In addition, SOPHiA GENETICS allows NOMAD Genetics to
retain full ownership of their data, saving time and expense, while
offering comprehensive genomic insights powered by deep learning
algorithms.
"Our products and solutions are designed to enable facilities
like NOMAD Genetics to more easily advance precision-medicine,"
said Ricardo Mendonca Filho, PhD,
Managing Director, LAPAC, SOPHiA GENETICS. "By leveraging our
technology, NOMAD Genetics can expedite their clinical research,
enabling them to make informed, data-driven decisions for LATAM
with greater efficiency."
Through the implementation of the SOPHiA GENETICS Platform,
NOMAD Genetics will be able to more quickly and accurately identify
HRD-positive cancers and utilize a streamlined workflow that will
help accelerate rare and inherited disease research.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook,
and Instagram.
To learn more about NOMAD Genetics, visit nomadlaboratorios.com,
or connect on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
|
1
https://www.sophiagenetics.com/science-hub/targeting-homologous-recombination-deficiency-hrd-in-cancer-research/
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nomad-genetics-is-live-on-the-sophia-genetics-platform-301851652.html
SOURCE SOPHiA GENETICS